Healthy Skepticism Library item: 2446

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Jedrey CM, Chaurette KA, Winn LB.
Pharmaceutical company-sponsored disease management programs.
Manag Care Q 2002 Win; 10:(1):56-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476660http://

Abstract:

On April 25, 2002, the Internal Revenue Service finalized the proposed Corporate Sponsorship regulations. The changes made in the final regulations pertain to the proposed $79 ceiling on disregarded benefits, the 2 percent threshold for disregarded benefits, the scope of disregarded benefits, Web site hyperlinks, the inclusion of certain electronic publications in the definition of periodicals, the valuation date for substantial return benefits, and the scope of use or acknowledgement. The proposed regulations were discussed in the Winter 2002 issue of Managed Care Quarterly in an article titled the same as this one. This article is based on the final IRS regulations and therefore supersedes the original article published in the Winter 2002 issue.

Keywords:
Disease Management* Drug Industry/economics Drug Industry/organization & administration* Financial Support Fraud/legislation & jurisprudence Hospitals, Voluntary/economics Hospitals, Voluntary/legislation & jurisprudence* Humans Interinstitutional Relations Liability, Legal Managed Care Programs/economics Managed Care Programs/legislation & jurisprudence* Organizational Affiliation Physician Self-Referral/legislation & jurisprudence Program Development/economics* Tax Exemption analysis United States managed care disease management programs PROMOTIONAL STRATEGIES: INDUSTRY REGULATIONS, CODES, GUIDELINES: DIRECT GOVERNMENT REGULATION SPONSORSHIP: HEALTH FACILITIES AND INSTITUTIONS